Previously Offered (depleted) Tissue Microarrays

Return to top

  1. CHTN2002N1 - "Test" TMA

    Description:

    TMA series CHTN2002N1: Purpose: To provide researchers with a tissue microarray of formalin fixed paraffin embedded samples that includes most of the cell types present in the human body. Most samples are of non-neoplastic adult tissue obtained from surgical resection specimens, fixed within one hour of removal from the donors. The fixative used is buffered zinc formaldehyde (3.7% formaldehyde) (Z-fix, Anatech, LTD., Battle Creek, MI). Exceptions: Parathyoid - tissue is from a benign parathyroid adenoma due to the limiting size and limited availability of normal parathyroid tissue. Lymphatics-tissue is from a benign lymphangioma, due to the difficulty in sampling normal lymphatics Central nervous system tissue - all obtained from autopsy specimens within 36 hours of death. TMA design: Each tissue type was sampled multiple times with 0.6 mm needle cores in the original array design. The CHTN2002N1 TMA series was constructed as 4 replicate TMA blocks, designated CHTN2002N1A, CHTN2002N1B, CHTN2002N1C, CHTN2002N1D

    Unstained histologic sections are 4 microns thick, on charged glass slides.

    Return to top

  2. CHTN2002T1 - "Test" TMA

    Description:

    TMA series CHTN2002T1 contains 5 human tissue types (colonic mucosa, endometrium, spleen, liver and uterine smooth muscle) in 0.6 mm and 2 mm spot sizes. These are useful for determining assay conditions and procedures before using more expensive comprehensiveTMA slides.

    Unstained histologic sections are 4 microns thick, on charged glass slides.

    Return to top

  3. CHTN2003CRCprog - Colorectal Carcinoma Progression

    Description:

    The CHTN2003CRCprog TMA contains up to 20 cases of non-neoplastic colonic mucosa, 14 cases of adenomatous polyps, 14 cases of primary colorectal adenocarcinomas, 7 cases of adenocarcinoma metastatic to regional lymph nodes and 7 cases of adenocarcinoma metastatic to distant sites. Each case is sampled three times with 0.6 mm cores.

    This TMA represents a limited number of cases that may detect strong trends in differential gene expression, and is intended for pilot surveys and generation of hypotheses. This TMA does not contain case numbers of sufficient quantity to prove the clinical utility of a marker.

    Unstained histologic sections are 4 microns thick, on charged glass slides.

    Return to top

  4. CHTN BrCaProg1 - Brea​st Cancer Progression

    Description:

    The CHTNBrCaProg1 TMA contains non-neoplastic breast tissue, ductal carcinoma in situ (DCIS), infiltrating ductal carcinoma of the breast, infiltrating lobular carcinoma of the breast, and cases of adenocarcinoma metastatic to regional lymph nodes. Each case is sampled one time with a 2 mm core. The TMA design includes 14 cases of non-neoplastic breast, 14 cases of DCIS, 21 cases of primary carcinoma and 7 cases of metastatic carcinoma. Histologic quality assurance limits ensure a minimum of 7 cases of non-neoplastic breast, 10 cases of infiltrating carcinoma primary to the breast and 4 cases of metatstatic carcinoma. Due to the difficulty in capturing pre-invasive neoplasia, a minimum number of DCIS cases is not being guaranteed.

    This TMA represents a limited number of cases that may detect strong trends in differential gene expression, and is intended for pilot surveys and generation of hypotheses. This TMA does not contain case numbers of sufficient quantity to prove the clinical utility of a marker.

    Unstained histologic sections are 4 microns thick, on charged glass slides.

    Return to top

  5. CHTN OvCa1 - Ovarian Carcinoma Survey

    Description:

    The CHTN OvCa1 TMA contains examples of the major histologic types of epithelial ovarian cancer . Each case is sampled four times with 0.6 mm cores. The TMA design includes 20 cases each of serous papillary carcinoma (well to moderately differentiated), clear cell carcinoma, endometrioid adenocarcinoma and mucinous adenocarcinoma). Another 20 cases of poorly and undifferentiated carcinoma are also provided.

    This TMA may detect strong trends in differential gene expression among the different histologic types of ovarian carcinoma, and is intended for pilot surveys and generation of hypotheses. This TMA is not designed to prove the clinical utility of prognostic biomarkers.

    Unstained histologic sections are 4 microns thick on charged glass slides.

    Return to top

  6. CHTN Test2 - Test Tissue Microarray

    Description:

    CHTN Test Tissue Microarrays (versions 2,3,4) contain lymphoid, epithelial and stromal tissue (spleen, colonic mucosa, prostate, liver, breast cancer and uterine smooth muscle) in 0.6 mm spot sizes. These are useful for determining assay conditions and procedures before using more expensive comprehensiveTMA slides.

    Unstained histologic sections are 4 microns thick on charged glass slides.

  7. CDP Breast Cancer Progression Tissue Microarray (Clinical Progression)

    Description:

    CDP Breast Cancer Progression Tissue Microarrays are designed to investigate differences in marker prevalence in three stages of invasive breast cancer: node-negative, node-positive and metastatic disease. This TMA set contains a total of 339 breast tissue cores, plus cell line and normal non-breast tissue controls. All of the invasive cases are primary breast cancers with a principal histology of ductal cancer. The CDP breast cancer progression TMA was designed by a National Cancer Institute biostatistician to ensure high statistical power for studies of stage specific markers of breast cancer.

    Unstained histologic sections are 4 microns thick on charged glass slides. 1 set consists of 6 TMA slides.

    Return to top

Return to top